Related Experiment Videos
Antithrombotic therapy in coronary ischaemia: the expanding role of low-molecular-weight heparin
1Department of Medicine, McMaster University, Hamilton, Ont, Canada.
Insights
Low-molecular-weight heparins (LMWHs) effectively reduce ischemic events in acute coronary syndromes. These agents offer a safe, cost-effective alternative to standard heparin for unstable coronary disease management.
Area of Science:
- Cardiology
- Pharmacology
- Internal Medicine
Background:
- Acute coronary syndromes (ACS) require effective antithrombotic therapy.
- Heparin is a standard treatment, but alternatives are sought for improved efficacy and safety.
Purpose of the Study:
- To evaluate the efficacy and safety of low-molecular-weight heparins (LMWHs) in managing acute coronary ischaemia.
- To compare LMWHs with standard heparin in clinical trials.
Main Methods:
- Review of clinical trial data on LMWHs in patients with unstable angina and non-Q-wave myocardial infarction.
- Analysis of comparative studies between LMWHs and unfractionated heparin.
Main Results:
- LMWHs significantly reduce major ischaemic outcomes in ACS.
- One study demonstrated superior efficacy of LMWH compared to standard heparin.
- Subcutaneous fixed-dose LMWH administration without monitoring offers cost savings.
Conclusions:
- LMWHs are safe and effective alternatives to standard heparin for unstable coronary disease.
- LMWHs provide practical and therapeutic advantages in managing acute coronary ischaemia.
Abstract:
Low-molecular-weight heparins (LMWHs) have been rigorously evaluated in the management of acute coronary ischaemia. The results of clinical trials suggest that LMWHs are effective in reducing major ischaemic outcomes in patients with unstable angina and non-Q-wave myocardial infarction. In one study, LMWH was shown to be more effective than heparin. The clinical utility of LMWHs given subcutaneously in a fixed-dose without the need for monitoring results in major cost savings. The accumulating evidence suggests that LMWHs are safe, effective alternatives to standard heparin in unstable coronary disease and offer practical and therapeutic advantages, representing an important advance in the management of acute coronary ischaemia.